Senzime AB (SEZI) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Senzime AB (SEZI) has a cash flow conversion efficiency ratio of -0.081x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-23.03 Million ≈ $-2.48 Million USD) by net assets (Skr283.50 Million ≈ $30.51 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See SEZI days of operational coverage to measure how many days the company can operate on defensive assets alone.
Senzime AB - Cash Flow Conversion Efficiency Trend (2006–2025)
This chart illustrates how Senzime AB's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Senzime AB Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Senzime AB ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Vakrangee Limited
NSE:VAKRANGEE
|
0.093x |
|
SRV Group plc
HE:SRV1V
|
0.076x |
|
e-LITECOM CO. Ltd
KQ:041520
|
-0.006x |
|
AGROB Immobilien AG
F:AGR
|
N/A |
|
Cintac
SN:CINTAC
|
0.119x |
|
CHAPEL DOWN GRP PLC LS-05
F:1U6
|
N/A |
|
Shanghai Shibei Hi-Tech Co Ltd B
SHG:900902
|
-0.011x |
|
Siebert Financial Corp
NASDAQ:SIEB
|
-0.296x |
Annual Cash Flow Conversion Efficiency for Senzime AB (2006–2025)
The table below shows the annual cash flow conversion efficiency of Senzime AB from 2006 to 2025. For the full company profile with market capitalisation and key ratios, see SEZI company net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | Skr304.46 Million ≈ $32.76 Million |
Skr-109.10 Million ≈ $-11.74 Million |
-0.358x | -16.98% |
| 2024-12-31 | Skr345.86 Million ≈ $37.22 Million |
Skr-105.94 Million ≈ $-11.40 Million |
-0.306x | -0.97% |
| 2023-12-31 | Skr375.48 Million ≈ $40.41 Million |
Skr-113.91 Million ≈ $-12.26 Million |
-0.303x | +41.91% |
| 2022-12-31 | Skr261.90 Million ≈ $28.18 Million |
Skr-136.78 Million ≈ $-14.72 Million |
-0.522x | +3.31% |
| 2021-12-31 | Skr150.58 Million ≈ $16.20 Million |
Skr-81.33 Million ≈ $-8.75 Million |
-0.540x | -225.94% |
| 2020-12-31 | Skr231.35 Million ≈ $24.90 Million |
Skr-38.34 Million ≈ $-4.13 Million |
-0.166x | +0.04% |
| 2019-12-31 | Skr163.69 Million ≈ $17.62 Million |
Skr-27.14 Million ≈ $-2.92 Million |
-0.166x | -56.49% |
| 2018-12-31 | Skr167.41 Million ≈ $18.02 Million |
Skr-17.73 Million ≈ $-1.91 Million |
-0.106x | -21.04% |
| 2017-12-31 | Skr140.46 Million ≈ $15.12 Million |
Skr-12.29 Million ≈ $-1.32 Million |
-0.088x | -15.36% |
| 2016-12-31 | Skr131.87 Million ≈ $14.19 Million |
Skr-10.00 Million ≈ $-1.08 Million |
-0.076x | +45.81% |
| 2015-12-31 | Skr45.81 Million ≈ $4.93 Million |
Skr-6.41 Million ≈ $-690.18K |
-0.140x | -60.40% |
| 2014-12-31 | Skr44.08 Million ≈ $4.74 Million |
Skr-3.85 Million ≈ $-414.05K |
-0.087x | +39.78% |
| 2013-12-31 | Skr37.46 Million ≈ $4.03 Million |
Skr-5.43 Million ≈ $-584.31K |
-0.145x | +23.55% |
| 2012-12-31 | Skr31.99 Million ≈ $3.44 Million |
Skr-6.06 Million ≈ $-652.57K |
-0.190x | -170.80% |
| 2011-12-31 | Skr27.87 Million ≈ $3.00 Million |
Skr-1.95 Million ≈ $-209.94K |
-0.070x | +27.67% |
| 2010-12-31 | Skr21.90 Million ≈ $2.36 Million |
Skr-2.12 Million ≈ $-228.10K |
-0.097x | -0.30% |
| 2009-12-31 | Skr16.61 Million ≈ $1.79 Million |
Skr-1.60 Million ≈ $-172.54K |
-0.096x | -664.63% |
| 2006-12-31 | Skr7.55 Million ≈ $812.29K |
Skr129.00K ≈ $13.88K |
0.017x | -- |
About Senzime AB
Senzime AB (publ), a medical device company, develops, manufactures, and markets algorithm-powered patient monitoring systems to increase patient safety during and after surgery in Europe and the United States. The company offers TetraGraph, quantitative train of-four (TOF) monitoring refined by real-world patient data; and ExSpiron, a non-invasive monitoring system that uses bioelectrical impeda… Read more